Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients

Journal of NeuroVirology

Volumn 13, Issue 6, 2007, Pages 504-512

  Garcia Montojo, Marta ^a   De Las Heras, Virginia ^a   Bartolome, Manuel ^a   Arroyo, Rafael ^a   Alvarez Lafuente, Roberto ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

HHV 6; Interferon beta; MMP 9; Multiple sclerosis; MxA; TIMP 1

Indexed keywords

GELATINASE B; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN HERPESVIRUS 6; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VIRUS GENOME; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; GTP-BINDING PROTEINS; HERPESVIRUS 6, HUMAN; HUMANS; INTERFERON-BETA; MATRIX METALLOPROTEINASE 9; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

HUMAN HERPESVIRUS 6; ORTHOMYXOVIRIDAE;

EID: 37549017273     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280701649670     Document Type: Article

References (37)

1. Ahlqvist, J., Fotheringham, J., Akhyani, N., Yaoo, K., Hahn, A Fogdell and Jacobson (2005) Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes. J NeurVirol, 11, pp. 384-394.
2. Alvarez-Lafuente, R., Martín-Estefanía, C., Heras, V De las, Castrillo, C., Cour, I., Picazo, J. J., de Seijas, E Varela and Arroyo, R. (2002) Prevalence of herpesvirus DNA in MS patients and healthy blood donnors. Acta Neurol Scand, 105, pp. 95-99.
3. Alvarez-Lafuente, R., Martín-Estefanía, C., Heras, V De las, Castrillo, C., Picazo, J. J., Varela, E. and Arroyo, R. (2002) Active human herpesvirus 6 infection in patients with multiple sclerosis. Arch Neurol, 59, pp. 929-933.
4. Avolio, C., Filippi, M., Tortorella, C., Rocca, M. A., Ruggieri, M., Agosta, F., Tomassini, V., Pozzilli, C., Stecchi, S., Giaquinto, P., Livrea, P. and Trojano, M. (2005) Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: Relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler, 11, pp. 441-446.
5. Cermelli, C., Berti, R., Soldan, S. S., Mayne, M., D'ambrosia, J. M., Ludwin, S. K. and Jacobson, S. (2003) High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis, 187, pp. 1377-1387.
6. Challoner, P. B., Smith, K. T., Parker, J. D., MacLeod, D. L., Coulter, S. N., Rose, T. M., Schultz, E. R., Bennett, J. L., Garber, R. L., Chang, M., Schad, P. A., Stewart, P. M., Nowinski, R. C., Brown, P. B. and Burmer, G. C. (1995) Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA, 92, pp. 7440-7444.
7. Chapenko, S., Millar, A., Nora, Z., Logina, I., Kukaine, R. and Murovska, M. (2003) Correlation between HHV-6 reactivation and multiple sclerosis disease activity. J Med Virol, 69, pp. 111-117.
8. Deisenhammer, F., Reindl, M. and Harvey, J. (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology, 52, pp. 1239-1243.
9. European Study Group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet, 352, pp. 1491-1497.
10. Gilli, F., Bertolotto, A., Sala, A., Hoffman, F., Capobianco, M., Malucchi, S., Glass, T., Kappos, L., Lindberg, R LP and Leppert, D. (2004) Neutralizing antibodies against IFN-β in multiple sclerosis: antagonization of IFN-β-mediated supp suppression of MMPs. Brain, 127, pp. 259-268.
11. Gilli, F., Sala, A., Bancote, C., Salacone, P., Gallo, M., Gaia, E. and Bertolotto, A. (2002) Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients. J Immunol Methods, 262, pp. 187-190.
12. Giovannoni, F., Munschauer 3rd, E. and Deisenhammer, F. (2002) Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry, 73, pp. 465-469.
13. Hickey, W. F., Hsu, B. L. and Kimura, H. (1991) T-lymphocyte entry into the central nervous system. J Neurosci Res, 28, pp. 254-260.
14. Higashikata, T., Yamagishi, M., Sasaki, H., Minatoya, K., Ogino, H., Ishibashi-Ueda, H., Hao, H., Nagaya, N., Tomoike, H. and Sakamoto, A. (2004) Application of real-time RT-PCR to quantifying gene expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human abdominal aortic aneurysm. Atherosclerosis, 177, pp. 353-360.
15. Hong, J., Tejada-Simón, M. V., Rivera, V. M., Zang, Y CQ and Zhang, J. Z. (2002) Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult scler, 8, pp. 237-242.
16. Hymas, W., Stevenson, J., Taggart, E. W. and Hillyard, D. (2005) Use of lyophilized standards for the calibration of a newly developed real time PCR assay for human herpes type six (HHV6) variants A and B. J Virol Methods, pp. 143-150.
17. Jordan, R. C., Macabeo-Ong, M., Shiboski, C. H., Dekker, N., Gininger, D. G., Wong, D. T. and Schmidt, B. L. (2004) Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res, 10, pp. 6460-6465.
18. Lee, M. A., Palace, J., Stabler, G., Ford, J., Gearing, A. and Miller, K. (1999) Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain, 122, pp. 191-197.
19. Lepert, D., Lindberg, R. L., Kappos, L. and Leib, S. L. (2001) Matrix metalloproteinases: Multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Rev, 36, pp. 249-257.
20. Medeiros, M., Sharma, V. K., Ding, R., Yamaji, K., Li, B., Muthukumar, T., Valderde-Rosas, S., Hernandez, A. M., Muñoz, R. and Suthanthiran, M. (2003) Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater. J Immunol Methods, 279, pp. 135-142.
21. Myhr, K. M., Ross, C., Nyland, H. I., Bendtzen, K. and Vedeler, C. A. (2000) Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. Neurology, 55, pp. 1569-1572.
22. Opdenakker, G., Steen, P E Van den, Dubos, B., Nelissen, I. and Van Damme, J. (2001) Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol, 69, pp. 851-859.
23. Pachner, A. R., Bertolotto, A. and Deisenhammer, F. (2003) Measurement of MxA or protein as a biomarker of IFNβ bioactivity. Neurology, 61, pp. S24-S26.
24. Pachner, A. R., Dail, D., Pak, E. and Narayan, K. (2005) The importance of measuring IFN-β antibodies bioactivity: Monitoring in MS patients and the effect of anti-IFN-β antibodies. J Neuroimmunol, 166, pp. 180-188.
25. Pachner, A. R., Narayan, K., Price, N., Hurd, M. and Dail, D. (2003) MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn, 7, pp. 17-25.
26. Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O'Connor, P., Monaghan, E., Li, D., Weinshenker, B. and EVIDENCE Study Group (2002) Evidence of Interferon Dose-response: European North American Comparative Efficacy, University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS. Neurology, 59, pp. 1496-1506.
27. Raine, C. S., Canella, B., Duijvestijn, A. M. and Cross, A. H. (1990) Homing to central nervous system vasculature by antigen-specific lymphocytes.II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab Invest, 63, pp. 476-489.
28. Rice, G. (2001) The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol, 58, pp. 1297-1298.
29. Ross, C., Clemmesen, K. M. and Svenson, M. (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol, 48, pp. 706-712.
30. Rudick, R. A., Simonian, N. A. and Alam, J. A. (1998) Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology, 50, pp. 1266-1272.
31. Sorensen, P. S., Ross, C., Clemmesen, K. M., Bendtzen, K., Frederiksen, J. L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., Stenager, E., Koch-Henriksen, N. and Danish Multiple Sclerosis Study Group (2003) Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet, 362, pp. 1184-1191.
32. Suhayl, D. J. (2002) Mechanism of action of interferons and glatiramer acetate in multiple sclerosis. Neurology, 58, pp. S3-S9.
33. Tejada-Simon, M. V., Zang, Y CQ, Hong, J., Rivera, V. M. and Zhang, J. Z. (2003) Cross-reactivity with myelin basic protein and human-herpesvirus-6 in multiple sclerosis. Ann Neurol, 53, pp. 189-197.
34. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology, 47, pp. 889-894.
35. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (2005) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology, 45, pp. 1277-1285.
36. Waubant, E., Goodkin, D., Bostrom, A., Bacchetti, P., Hietpas, J., Lindberg, R. and Leppert, D. (2003) IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology, 60, pp. 52-57.
37. Yong, V. W., Krekoski, C. A., Forsyth, P., Bell, R. and Edwards, D. R. (1998) Matrix metalloproteases and disease of the CNS. Trends Neurosci, 21, pp. 75-80.